# A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

> **NCT01433250** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** AIN457
- **DRUG:** AIN457

## Key facts

- **NCT ID:** NCT01433250
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433250, "A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01433250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*